Development of MHC-restricted cell therapy using brain-tumor specific antigen and its chemicals

点击翻译按钮获取中文摘要

We have been developing MHC-restricted cell therapy using brain-tumor specific antigen and its chemicals. At first we identified X-linked X-linked inhibitor of apoptosis protein (XIAP), Aurora-B, c-Jun N-terminal kinase (JNK) and Fas as brain tumor-specific or associated antigens. Thereafter we designed their chemicals using methods of structure-based drug design or genome-information drug design, confirming their biological activities in cultured human glioma cells. Until now we operated genetic medicines in Japan for over 20 years and provided medical services to patients with formidable diseases such as malignant glioma and malignant melanoma. The results were succeeded to The Center for Genetic and Regenerative Medicine (CGRM) in our Hospital, which is an institute to put advanced medicine into practice in Nagoya University Hospital. There we are responsible for process development, validation, and GMP (Good Manufacturing Practice) production of a broad range of novel cell and gene therapies including dendritic cell vaccines, antigen-specific CTLs (cytotoxic T lymphocytes), plasmid DNA, liposomes with plasmid DNA, and bio-materials for regenerative medicine, in support of some clinical trials. In 2006 this CGRM gained ISO (International Organization for Standardization) 9001:2000 and 13485:2003 Accreditation. We became the first academic institute in Japan to achieve the ISO Quality. We opened clinical trials for patients with recurrent malignant glioma using MHC-restricted cells against some brain-tumor specific or associated antigen